Home / Health / Pancreatic Cancer Pill Doubles Survival Time
Pancreatic Cancer Pill Doubles Survival Time
13 Apr
Summary
- New pill daraxonrasib nearly doubles survival for late-stage pancreatic cancer patients.
- Drug showed a 60% reduced risk of death compared to chemotherapy alone.
- Patients on the pill lived an average of 13.2 months, vs. 6.7 months on chemo.
A new once-daily pill, daraxonrasib, shows remarkable promise for treating late-stage pancreatic cancer in the U.S., nearly doubling patient survival duration compared to traditional chemotherapy. In a Phase 3 trial, daraxonrasib significantly reduced the risk of death by 60% for patients.
This revolutionary treatment offers a potential lifeline for individuals with pancreatic cancer, a disease with notoriously poor prognosis. The drug's efficacy is attributed to its unique ability to block the mutated RAS gene, a known driver of various cancers.
Revolution Medicines, the company behind daraxonrasib, plans to submit its findings to the U.S. Food and Drug Administration for approval. The drug has already garnered attention, including from former Senator Ban Sasse, who reported significant tumor shrinkage despite experiencing notable side effects.
While side effects like rash, fatigue, and nausea are noted, they are comparable to those associated with chemotherapy. Experts emphasize the need for further large-scale data to fully assess daraxonrasib's long-term impact and its precise comparison to existing treatments.
